Literature DB >> 29178011

Pyridoxine-dependent epilepsies: an observational study on clinical, diagnostic, therapeutic and prognostic features in a pediatric cohort.

Raffaele Falsaperla1, Maria Stella Vari2, Irene Toldo3, Alessandra Murgia3, Stefano Sartori3, Marilena Vecchi3, Agnese Suppiej3, Alberto Burlina4, Mario Mastrangelo5, Vincenzo Leuzzi5, Valentina Marchiani6, Paola De Liso5, Giuseppe Capovilla7, Pasquale Striano2, Giovanna Vitaliti8.   

Abstract

The aim of our study was to describe the clinical, electroencephalogram, molecular findings and the diagnostic and therapeutic flow-chart of children with pyridoxine-dependent epilepsies (PDEs). We performed a retrospective observational study on children with PDEs, diagnosed and followed-up in Italian Pediatric Departments. In each centre, the authors collected data from a cohort of children admitted for intractable seizures, responsive to pyridoxine administration and resistant to other anticonvulsant therapies. Data were retrospectively analysed from January 2016 to January 2017. Sixteen patients (13 males, and 3 females) were included. We found that 93.75% of patients underwent conventional anticonvulsant therapy before starting pyridoxine administration and 62.5% had ex-juvantibus diagnosis, as specific serum diagnostic tests had been performed in only 37.5% of patients by alpha-AASA and pipecolic acid blood and urine dosage. The most common type of seizure was generalized tonic-clonic in 7 patients and the most common EEG pattern was characterized by a "burst suppression" pattern. Before pyridoxine administration, other anticonvulsant drugs were used in 93.75% of patients, with consequent onset of drug-resistance. Phenobarbital was the most frequently used drug as first-line treatment. The importance of our study relies on the need of a deeper knowledge of PDEs in terms of early diagnosis, avoiding incorrect treatment and related adverse events, clinical and EEG pathognomonic features, and genetic aspects of the disease.

Entities:  

Keywords:  Cohort; Dependent epilepsies; Diagnosis; Observational study; Pediatric age; Pyridoxine; Treatment

Mesh:

Substances:

Year:  2017        PMID: 29178011     DOI: 10.1007/s11011-017-0150-x

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  22 in total

1.  Epidemiology of pyridoxine dependent seizures in the Netherlands.

Authors:  J V Been; L A Bok; P Andriessen; W O Renier
Journal:  Arch Dis Child       Date:  2005-09-13       Impact factor: 3.791

Review 2.  Targeting inflammation as a therapeutic strategy for drug-resistant epilepsies: an update of new immune-modulating approaches.

Authors:  Giovanna Vitaliti; Piero Pavone; Fahad Mahmood; Giuseppe Nunnari; Raffaele Falsaperla
Journal:  Hum Vaccin Immunother       Date:  2014-03-07       Impact factor: 3.452

3.  Pyridoxine dependent epilepsy: a suggestive electroclinical pattern.

Authors:  R Nabbout; C Soufflet; P Plouin; O Dulac
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-09       Impact factor: 5.747

4.  Seizures and paroxysmal events: symptoms pointing to the diagnosis of pyridoxine-dependent epilepsy and pyridoxine phosphate oxidase deficiency.

Authors:  Bernhard Schmitt; Matthias Baumgartner; Philippa B Mills; Peter T Clayton; Cornelis Jakobs; Elmar Keller; Gabriele Wohlrab
Journal:  Dev Med Child Neurol       Date:  2010-03-29       Impact factor: 5.449

5.  Pyridoxine-dependent seizures: demographic, clinical, MRI and psychometric features, and effect of dose on intelligence quotient.

Authors:  P Baxter; P Griffiths; T Kelly; D Gardner-Medwin
Journal:  Dev Med Child Neurol       Date:  1996-11       Impact factor: 5.449

6.  Mutations in PROSC Disrupt Cellular Pyridoxal Phosphate Homeostasis and Cause Vitamin-B6-Dependent Epilepsy.

Authors:  Niklas Darin; Emma Reid; Laurence Prunetti; Lena Samuelsson; Ralf A Husain; Matthew Wilson; Basma El Yacoubi; Emma Footitt; W K Chong; Louise C Wilson; Helen Prunty; Simon Pope; Simon Heales; Karine Lascelles; Mike Champion; Evangeline Wassmer; Pierangelo Veggiotti; Valérie de Crécy-Lagard; Philippa B Mills; Peter T Clayton
Journal:  Am J Hum Genet       Date:  2016-12-01       Impact factor: 11.025

7.  Pyridoxine-dependent seizures: 10-year follow-up of eight cases.

Authors:  Roshan Koul
Journal:  Neurol India       Date:  2009 Jul-Aug       Impact factor: 2.117

8.  Atypical presentations of pyridoxine-dependent seizures: a treatable cause of intractable epilepsy in infants.

Authors:  F Goutières; J Aicardi
Journal:  Ann Neurol       Date:  1985-02       Impact factor: 10.422

9.  An intriguing "silent" mutation and a founder effect in antiquitin (ALDH7A1).

Authors:  Gajja S Salomons; Levinus A Bok; Eduard A Struys; Lorna Landegge Pope; Patricia S Darmin; Philippa B Mills; Peter T Clayton; Michèl A Willemsen; Cornelis Jakobs
Journal:  Ann Neurol       Date:  2007-10       Impact factor: 10.422

10.  Pyridoxine-dependent epilepsy due to antiquitin deficiency: achieving a favourable outcome.

Authors:  Renata Oliveira; Cristina Pereira; Fidjy Rodrigues; Claudia Alfaite; Paula Garcia; Conceição Robalo; Isabel Fineza; Olavo Gonçalves; Eduard Struys; Gajja Salomons; Cornelis Jakobs; Luísa Diogo
Journal:  Epileptic Disord       Date:  2013-12       Impact factor: 1.819

View more
  3 in total

1.  A Rare Presentation Characterized by Epileptic Spasms in ALDH7A1, Pyridox(am)ine-5'-Phosphate Oxidase, and PLPBP Deficiency.

Authors:  Xianru Jiao; Pan Gong; Yue Niu; Yuehua Zhang; Zhixian Yang
Journal:  Front Genet       Date:  2022-04-12       Impact factor: 4.772

2.  Analysis of the Phenotypic Variability as Well as Impact of Early Diagnosis and Treatment in Six Affected Families With ALDH7A1 Deficiency.

Authors:  Xianru Jiao; Pan Gong; Ye Wu; Yuehua Zhang; Zhixian Yang
Journal:  Front Genet       Date:  2021-04-01       Impact factor: 4.599

3.  A case for newborn screening for pyridoxine-dependent epilepsy.

Authors:  Curtis R Coughlin; Laura A Tseng; Clara D M van Karnebeek
Journal:  Cold Spring Harb Mol Case Stud       Date:  2022-03-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.